Biotech Values

[Rocky3]

GILD - I am assuming others are watching the script numbers too.

Since it looks like the likely sales of the current product are 150-300% higher than projections (saw a $9B+ run rate number this morning), how will that affect the later product of GILD (and the ABBV/ENTA product)? I am surprised that the market has not rewarded GILD more now. My best guess is that future sales were already priced in and current sales are viewed as stealing from future sales. Or they think there will be a big decline soon (which sure doesn't seem likely). Others views?

Under the market inefficiency theory, I have been adding a lot of GILD. Now larger than my ENTA position, but still much smaller than a major overweight where MNTA still is, which is smaller than the SEPR position from yesteryear.

JMO.